Medical School · Year 1 · Respiratory · includes a quiz and discussion video

Lecture 13: Respiratory Failure

Unit 1.8: Respiratory System

Learning Objectives

By the end of this lecture, students will be able to:

1. Define and classify respiratory failure (Type I and Type II)
2. Describe the pathophysiology of hypoxemic and hypercapnic respiratory failure
3. Explain the causes and mechanisms of acute respiratory distress syndrome (ARDS)
4. Describe oxygen delivery systems and their indications
5. Explain the principles of mechanical ventilation
6. Apply concepts of respiratory failure management to clinical scenarios

Definition and Classification

Respiratory failure occurs when the respiratory system fails to maintain adequate gas exchange, resulting in hypoxemia, hypercapnia, or both. Classification guides diagnosis and treatment selection.

Types of Respiratory Failure

The fundamental classification distinguishes between oxygenation failure and ventilation failure. Type I (hypoxemic) respiratory failure is defined by PaO2 less than 60 mmHg while breathing room air, with normal or low PaCO2. The primary problem is oxygenation—getting oxygen from alveoli into blood—while ventilation (CO2 elimination) remains adequate or even increased through compensatory hyperventilation. Type II (hypercapnic) respiratory failure is defined by PaCO2 greater than 50 mmHg (hypercapnia), reflecting failure to adequately ventilate. PaO2 may be reduced secondary to alveolar hypoventilation, but the defining feature is carbon dioxide retention.

Acute Versus Chronic

The time course of respiratory failure has important implications. Acute respiratory failure develops over hours to days, with insufficient time for metabolic compensation. Arterial blood gases show abnormal pH reflecting respiratory acidosis (in Type II) or the underlying process. Chronic respiratory failure develops over weeks to months, allowing renal compensation for respiratory acidosis. Patients with chronic hypercapnia (such as severe COPD) may have near-normal pH despite elevated PaCO2, as the kidneys retain bicarbonate. Acute-on-chronic respiratory failure occurs when a patient with chronic respiratory insufficiency experiences an acute decompensation.

Combined Failure

Type I and Type II failure may coexist. For example, a patient with severe COPD exacerbation complicated by pneumonia may demonstrate both hypoxemia from V/Q mismatch and shunt, and hypercapnia from ventilatory failure. Management must address both problems.

<image>Panel A: Type I respiratory failure arterial blood gas panel showing PaO2 55 mmHg highlighted in red, PaCO2 32 mmHg low-normal, and pH 7.45 indicating compensatory hyperventilation. Panel B: Type II respiratory failure arterial blood gas panel showing PaO2 58 mmHg, PaCO2 65 mmHg highlighted in red, and pH 7.28 indicating respiratory acidosis. Panel C: Timeline comparing acute versus chronic respiratory failure: acute with rapid deterioration over days and abnormal pH without compensation, chronic with gradual deterioration over months and near-normal pH from renal bicarbonate retention. Panel D: Combined Type I and Type II failure showing a patient figure with both low PaO2 and high PaCO2, with lung diagram illustrating V/Q mismatch areas causing hypoxemia and reduced minute ventilation causing hypercapnia.</image>

Hypoxemic Respiratory Failure (Type I)

Understanding the mechanisms of hypoxemia is essential for diagnosis and treatment selection.

Mechanisms of Hypoxemia

Five primary mechanisms cause hypoxemia, distinguishable by their response to supplemental oxygen and effect on the alveolar-arterial oxygen gradient. Low inspired oxygen (low FiO2) occurs at high altitude or with oxygen-depleted environments; the A-a gradient remains normal, and supplemental oxygen corrects hypoxemia readily. V/Q mismatch is the most common cause in clinical practice, occurring when some lung regions have reduced ventilation relative to perfusion (low V/Q units). Blood passing through these areas is incompletely oxygenated. The A-a gradient is elevated, but hypoxemia responds well to supplemental oxygen because oxygen can still reach functioning alveoli.

Shunt represents the extreme of V/Q mismatch—blood passes through completely unventilated areas (V/Q = 0) or through anatomical bypasses. Because this blood never contacts ventilated alveoli, supplemental oxygen cannot correct the hypoxemia (the hallmark of shunt). The A-a gradient is markedly elevated. Causes include intrapulmonary shunts (ARDS, severe pneumonia, pulmonary edema) and intracardiac shunts (right-to-left).

Diffusion impairment occurs when the alveolar-capillary membrane is thickened (interstitial lung disease) or transit time is shortened (exercise with elevated cardiac output). Hypoxemia is typically mild at rest but worsens with exercise; it responds to supplemental oxygen. Hypoventilation causes hypoxemia by reducing alveolar oxygen tension (PAO2) according to the alveolar gas equation; the A-a gradient remains normal, and supplemental oxygen corrects hypoxemia, though the underlying hypercapnia persists.

Causes of Type I Respiratory Failure

Type I respiratory failure results from diverse pathology affecting gas exchange. Pulmonary parenchymal diseases include pneumonia, which causes V/Q mismatch and shunt; ARDS, characterized by diffuse alveolar damage and refractory hypoxemia; and pulmonary edema, both cardiogenic and noncardiogenic. Vascular causes include pulmonary embolism (dead space and V/Q mismatch) and pulmonary hypertension. Airway diseases in severe exacerbation (asthma, COPD) cause V/Q mismatch. Interstitial lung diseases impair diffusion. Pleural pathology including large effusions and tension pneumothorax compromises ventilation and perfusion.

<image>Panel A: V/Q mismatch showing an alveolus with partially blocked airway but preserved perfusion and moderate blood desaturation that responds to supplemental oxygen; shunt showing a completely unventilated alveolus filled with fluid with blood fully desaturated and poor response to oxygen. Panel B: Diffusion impairment showing thickened alveolar membrane with oxygen molecules slowly crossing that responds to supplemental oxygen; hypoventilation showing underventilated alveolus with elevated CO2 and reduced O2 with normal A-a gradient. Panel C: Low FiO2 showing normal alveolus with reduced inspired oxygen at high altitude, maintaining a normal A-a gradient and responding well to supplemental oxygen. Panel D: Summary table of all five mechanisms with columns for A-a gradient status (normal versus elevated) and response to supplemental oxygen (good, poor, or variable) for each mechanism.</image>

Hypercapnic Respiratory Failure (Type II)

The Ventilation Equation

Carbon dioxide elimination depends on alveolar ventilation according to the equation: PaCO2 = (VCO2 × 0.863) / VA, where VCO2 is CO2 production and VA is alveolar ventilation. Alveolar ventilation equals minute ventilation minus dead space ventilation: VA = VE × (1 - VD/VT). Thus, hypercapnia results from decreased minute ventilation, increased dead space, or (rarely as a sole cause) increased CO2 production.

Mechanisms and Causes

Hypercapnic respiratory failure results from impaired ventilation at any level from the brainstem to the lung parenchyma. Decreased respiratory drive (CNS depression) occurs with drug overdose (opioids, sedatives), stroke affecting respiratory centers, and central sleep apnea. Spinal cord pathology, particularly high cervical injuries (C3-C5 affecting phrenic nerve), eliminates diaphragmatic function. Peripheral nerve disorders include Guillain-Barré syndrome and phrenic nerve injury. Neuromuscular junction disease includes myasthenia gravis and botulism. Respiratory muscle weakness occurs with muscular dystrophy and muscle fatigue from prolonged increased work of breathing.

Chest wall abnormalities impair the mechanical bellows function: severe kyphoscoliosis restricts thoracic expansion, flail chest disrupts chest wall mechanics, and obesity (particularly obesity hypoventilation syndrome) increases the work of breathing while reducing chest wall compliance. Severe airway obstruction in COPD and asthma increases airway resistance, causing incomplete exhalation and air trapping (dynamic hyperinflation), which places respiratory muscles at mechanical disadvantage.

Clinical Manifestations

Hypercapnia produces characteristic clinical findings reflecting CO2's effects on the central nervous system and cardiovascular system. Altered mental status ranging from confusion to somnolence to coma reflects CO2 narcosis. Headache results from cerebral vasodilation. Tremor and asterixis (flapping tremor at the wrists) indicate encephalopathy. Warm, flushed skin and bounding pulses result from CO2-induced vasodilation and increased cardiac output.

<image>Panel A: Central nervous system and spinal causes of Type II respiratory failure: brainstem with drug overdose pill bottle and stroke lesion affecting respiratory drive, and spinal cord with high cervical injury at C4 vertebra eliminating diaphragmatic function. Panel B: Peripheral nerve and neuromuscular causes: Guillain-Barre syndrome with demyelinating nerve, phrenic nerve injury with arrow to diaphragm, myasthenia gravis with antibodies at the neuromuscular junction, and muscular dystrophy with atrophied muscle fibers. Panel C: Chest wall and airway causes: kyphoscoliosis with curved spine, obesity with large abdomen compressing the thorax, flail chest with broken rib segments, and severe COPD and asthma with air trapping and dynamic hyperinflation diagram. Panel D: Clinical signs of hypercapnia in a sidebar: confused face indicating CO2 narcosis, asterixis at the wrists, vasodilated blood vessels with warm flushed skin, and the ventilation equation relating PaCO2 to alveolar ventilation.</image>

Acute Respiratory Distress Syndrome

ARDS represents a severe form of acute lung injury characterized by diffuse alveolar damage and refractory hypoxemia.

Berlin Definition

The Berlin criteria define ARDS with four components. Timing requires onset within one week of a known clinical insult or new/worsening respiratory symptoms. Imaging must demonstrate bilateral opacities on chest radiograph or CT not fully explained by effusions, atelectasis, or nodules. Origin specifies that respiratory failure is not fully explained by cardiac failure or fluid overload; objective assessment such as echocardiography is needed if no risk factor is identified. Oxygenation criteria require PaO2/FiO2 ratio of 300 or less with PEEP of at least 5 cmH2O.

Severity Classification

ARDS severity is stratified by the PaO2/FiO2 ratio (P/F ratio), with important prognostic and therapeutic implications. Mild ARDS has a P/F ratio of 200-300 and carries approximately 27% mortality. Moderate ARDS has a P/F ratio of 100-200 with 32% mortality. Severe ARDS has a P/F ratio of 100 or less with approximately 45% mortality. Severity guides escalation of therapy, with severe ARDS warranting consideration of rescue measures.

Causes

ARDS results from either direct (pulmonary) or indirect (extrapulmonary) insults. Direct causes affect the lung primarily: pneumonia (bacterial, viral including COVID-19), aspiration of gastric contents, inhalation injury, and pulmonary contusion. Indirect causes involve systemic processes that secondarily damage the lung: sepsis (the most common indirect cause), severe pancreatitis, massive transfusion (TRALI), and severe trauma with shock.

Pathophysiology

ARDS progresses through three overlapping phases. The exudative phase (days 1-7) features diffuse alveolar damage with alveolar flooding, hyaline membrane formation from precipitated proteins, and type I pneumocyte necrosis. Widespread surfactant dysfunction leads to atelectasis. Pulmonary edema is non-cardiogenic (PCWP less than 18 mmHg). Clinical manifestations include severe hypoxemia refractory to oxygen, bilateral infiltrates, and markedly decreased lung compliance.

The proliferative phase (days 7-21) involves organization and early repair. Type II pneumocytes proliferate to regenerate alveolar epithelium. Fibroblasts begin laying down collagen. Some patients improve during this phase; others progress to fibrosis. The fibrotic phase (after 3 weeks) affects a subset of patients who develop extensive pulmonary fibrosis, causing persistent gas exchange abnormalities and reduced lung compliance.

<image>Panel A: Berlin definition criteria as four boxes with checkmarks: timing with calendar showing less than 1 week, bilateral opacities on chest X-ray with diffuse white-out, cardiac failure excluded by echocardiogram with normal ejection fraction, and PaO2/FiO2 ratio 300 or less with PEEP at least 5 cmH2O. Panel B: Severity stratification horizontal bar from mild in green with P/F 200-300 and 27% mortality, through moderate in yellow with P/F 100-200 and 32% mortality, to severe in red with P/F 100 or less and 45% mortality. Panel C: Pathophysiology phases: exudative showing alveolar flooding, hyaline membranes, and necrotic type I cells during days 1-7; proliferative showing regenerating type II cells and fibroblast infiltration during days 7-21; and fibrotic showing collagen deposition and honeycomb appearance after 3 weeks. Panel D: Cause icons divided into direct pulmonary insults including pneumonia, aspiration, and smoke inhalation, and indirect extrapulmonary insults including sepsis with systemic inflammation, pancreatitis, and transfusion-related acute lung injury.</image>

ARDS Management

Management of ARDS focuses on supportive care while treating the underlying cause, with specific attention to lung-protective ventilation strategies.

Supportive Care Principles

Treating the underlying cause is paramount—antibiotics for sepsis, source control for abdominal infections. Conservative fluid management avoids excessive positive fluid balance, which worsens pulmonary edema; patients should be euvolemic or slightly negative. DVT prophylaxis prevents thromboembolic complications during prolonged immobilization. Early enteral nutrition is preferred when feasible. Sedation should be minimized, with daily awakening trials to avoid oversedation.

Lung-Protective Ventilation

The cornerstone of ARDS management is ventilation that minimizes additional lung injury. Ventilator-induced lung injury (VILI) results from overdistension (volutrauma/barotrauma) and cyclic opening and closing of atelectatic lung units (atelectrauma). The ARDSNet protocol established low tidal volume ventilation as standard of care.

Key targets include: Tidal volume of 4-6 mL/kg of ideal body weight (based on height, not actual weight)—this is lower than traditional volumes but prevents overdistension. Plateau pressure (measured during an inspiratory pause) should remain at or below 30 cmH2O. Driving pressure (plateau pressure minus PEEP) should be less than 15 cmH2O; lower driving pressure is associated with improved survival. PEEP is set to maintain alveolar recruitment and oxygenation; various PEEP/FiO2 tables guide selection. FiO2 is titrated to achieve SpO2 of 88-95%—permissive hypoxemia accepts slightly lower oxygen levels to avoid toxic FiO2.

Rescue Therapies

When initial management fails, rescue therapies may improve outcomes. Prone positioning improves V/Q matching by redistributing perfusion to better-ventilated anterior lung regions and recruiting atelectatic dorsal lung. For moderate-severe ARDS (P/F less than 150), prone positioning for at least 16 hours daily reduces mortality. Neuromuscular blockade may improve outcomes in severe ARDS by eliminating patient-ventilator dyssynchrony and reducing oxygen consumption. Inhaled pulmonary vasodilators (nitric oxide, epoprostenol) may improve oxygenation as salvage therapy, though survival benefit is unproven. Extracorporeal membrane oxygenation (ECMO) provides external gas exchange for refractory cases, serving as a bridge to recovery or transplant.

What to Avoid

High tidal volumes increase mortality. High plateau pressures cause barotrauma (pneumothorax, pneumomediastinum). Excessive fluid resuscitation worsens pulmonary edema. Oxygen toxicity from prolonged high FiO2 contributes to alveolar damage.

<image>Panel A: Ventilator screen with key lung-protective settings: tidal volume 4-6 mL/kg ideal body weight with IBW formula, plateau pressure 30 cmH2O or less, driving pressure less than 15 cmH2O shown as plateau minus PEEP on pressure waveform, PEEP/FiO2 table, and FiO2 targeting SpO2 88-95%. Panel B: Rescue therapies including prone positioning with patient face-down showing redistribution of ventilation and perfusion with timer of 16 or more hours per day, neuromuscular blockade with blocked junction, inhaled vasodilators with NO molecule entering pulmonary vessels, and ECMO circuit from patient through oxygenator. Panel C: Red avoid box listing high tidal volumes, high plateau pressures, excessive fluids, and prolonged high FiO2 as harmful practices. Panel D: Ventilator-induced lung injury rationale showing overdistension leading to volutrauma, cyclic atelectasis leading to atelectrauma, and the combined effect creating a progressive lung injury spiral.</image>

Oxygen Delivery Systems

Selecting the appropriate oxygen delivery device depends on oxygen requirements and clinical scenario.

Low-Flow Systems

Low-flow devices deliver oxygen at rates below the patient's inspiratory flow, meaning room air is entrained and the actual FiO2 varies with breathing pattern. Nasal cannula delivers 1-6 L/min, providing approximately 24-44% FiO2, with each additional liter increasing FiO2 by roughly 4%. It is comfortable and allows eating and speaking but provides variable FiO2 depending on respiratory rate and pattern.

Simple face masks require minimum flow of 5 L/min to prevent CO2 rebreathing and deliver 35-50% FiO2 at flows of 5-10 L/min. Partial rebreather masks have a reservoir bag that fills with oxygen during exhalation; breathing from this reservoir increases FiO2 to 50-70% at flows of 10-15 L/min. Non-rebreather masks add one-way valves to prevent room air entrainment, theoretically delivering 60-80% FiO2, though in practice true non-rebreathing is rarely achieved.

High-Flow Systems

High-flow systems deliver oxygen at or above the patient's inspiratory flow, providing more consistent FiO2. Venturi masks use the Bernoulli principle to entrain a precise amount of room air, delivering accurate FiO2 ranging from 24-50% depending on the color-coded adapter selected. They are valuable when precise oxygen control is important, such as in COPD patients at risk of hypercapnia.

High-flow nasal cannula (HFNC) represents a significant advancement, delivering heated and humidified oxygen at flows of 30-60 L/min through wide-bore nasal prongs. Benefits include accurate FiO2 delivery (21-100%) because high flow meets inspiratory demand, modest PEEP effect (approximately 1 cmH2O per 10 L/min with mouth closed), dead space washout improving ventilatory efficiency, and improved comfort compared to non-invasive ventilation. HFNC is increasingly used as first-line therapy for hypoxemic respiratory failure.

<image>Panel A: Low-flow oxygen devices in order of increasing FiO2: nasal cannula with simple prongs delivering 1-6 L/min at FiO2 24-44% with plus 4% per liter formula, and simple face mask delivering 5-10 L/min at FiO2 35-50% with minimum 5 L/min requirement. Panel B: Higher-capacity low-flow devices: partial rebreather with reservoir bag delivering 10-15 L/min at FiO2 50-70%, and non-rebreather with one-way valves delivering 10-15 L/min at FiO2 60-80%. Panel C: High-flow devices: Venturi mask with color-coded adapters labeled blue 24%, white 28%, yellow 35%, red 40%, green 60% using the Bernoulli effect for precise air entrainment; high-flow nasal cannula connected to heated humidifier and blender delivering 30-60 L/min at 21-100% FiO2. Panel D: Oxygen device selection guide matching severity to device: mild hypoxemia to nasal cannula, moderate to Venturi or simple mask, severe to HFNC or NIV, and refractory to intubation and mechanical ventilation.</image>

Non-Invasive Ventilation

Non-invasive ventilation (NIV) delivers positive pressure ventilation through a mask interface rather than an endotracheal tube, avoiding the complications of intubation while supporting ventilation.

Modes

Two primary modes are used. CPAP (continuous positive airway pressure) delivers a single level of continuous pressure throughout the respiratory cycle. It does not augment ventilation but recruits alveoli, improves oxygenation, and reduces work of breathing. BiPAP (bilevel positive airway pressure) delivers two pressure levels: higher pressure during inspiration (IPAP) and lower pressure during expiration (EPAP). The difference between IPAP and EPAP provides pressure support that augments ventilation. IPAP reduces work of breathing; EPAP provides the benefits of CPAP.

Evidence-Based Indications

NIV has strongest evidence in specific scenarios. COPD exacerbation with acute hypercapnic respiratory failure is the premier indication; NIV reduces intubation rates, mortality, and length of stay. BiPAP is typically initiated at IPAP 10-15 and EPAP 4-6, titrated to improve pH and reduce work of breathing. Target SpO2 in COPD is 88-92% to avoid suppressing hypoxic respiratory drive.

Acute cardiogenic pulmonary edema responds well to CPAP or BiPAP, which reduces both preload (by increasing intrathoracic pressure) and afterload (by reducing transmural LV pressure), while recruiting fluid-filled alveoli. NIV is an adjunct to standard therapy (diuretics, vasodilators).

Other evidence-supported uses include immunocompromised patients (where avoiding intubation is particularly beneficial), post-extubation to prevent reintubation, and chest wall trauma with flail chest.

Contraindications

Absolute contraindications include cardiac or respiratory arrest, facial trauma or burns precluding mask fit, inability to protect the airway, life-threatening hypoxemia requiring immediate intubation, and hemodynamic instability. Relative contraindications include agitation, excessive secretions, bowel obstruction, and recent esophageal surgery.

Monitoring for Failure

NIV success should be assessed within 1-2 hours. Signs of failure requiring escalation to intubation include worsening mental status, no improvement or worsening of pH and PaCO2, persistent tachypnea or accessory muscle use, hemodynamic deterioration, and inability to tolerate the mask. Delayed intubation in failing NIV worsens outcomes.

<image>Panel A: CPAP mode showing single-level constant positive pressure waveform with patient diagram illustrating alveolar recruitment and reduced work of breathing; BiPAP mode showing two-level pressure waveform with IPAP during inspiration and EPAP during expiration, pressure support equal to IPAP minus EPAP, and augmented ventilation. Panel B: Evidence-based indications: COPD exacerbation with strong evidence rating showing pursed-lip breathing patient and BiPAP settings, and cardiogenic pulmonary edema with strong evidence showing heart failure icon and CPAP/BiPAP reducing preload and afterload. Panel C: Contraindications shown as facial trauma precluding mask fit, unconscious patient unable to protect airway, and hemodynamically unstable vital signs requiring immediate intubation. Panel D: Failure monitoring checklist including mental status check, ABG trend assessment, and work of breathing evaluation, with decision box leading to intubation if not improving within 1-2 hours.</image>

Mechanical Ventilation Principles

When non-invasive measures fail, invasive mechanical ventilation provides definitive airway control and ventilatory support.

Indications for Intubation

Intubation is indicated when other measures cannot adequately support gas exchange or when airway protection is required. Hypoxemic failure unresponsive to non-invasive therapy (persistent PaO2 less than 60 mmHg despite high FiO2) requires invasive ventilation. Hypercapnic failure with rising CO2 and deteriorating mental status, particularly when NIV fails or is contraindicated, necessitates intubation. Airway protection is needed when patients cannot clear secretions or when level of consciousness (typically GCS 8 or less) creates aspiration risk. Anticipated clinical decline—impending respiratory arrest, pre-procedure in unstable patients, or progressive shock—often requires preemptive intubation.

Ventilator Modes

Volume control (VC) ventilation delivers a set tidal volume with each breath; the ventilator generates whatever pressure is required to deliver that volume. Advantage: guaranteed minute ventilation. Disadvantage: high pressures if compliance decreases. Pressure control (PC) ventilation delivers breaths at a set inspiratory pressure; tidal volume varies with compliance and resistance. Advantage: limits peak pressures. Disadvantage: variable minute ventilation.

Pressure support (PS) provides patient-triggered breaths with a set level of inspiratory pressure support; the patient controls rate, inspiratory time, and tidal volume. It is used for spontaneous breathing patients and during weaning. SIMV (synchronized intermittent mandatory ventilation) combines mandatory ventilator breaths with patient-triggered breaths, either spontaneous or with pressure support.

Key Ventilator Settings

FiO2 (fraction of inspired oxygen) is titrated to achieve target oxygen saturation. Tidal volume is typically 6-8 mL/kg ideal body weight, lower in ARDS. Respiratory rate is set to achieve adequate minute ventilation. PEEP (positive end-expiratory pressure) prevents alveolar collapse and improves oxygenation; it is set based on oxygenation needs and lung mechanics. I:E ratio (inspiratory to expiratory time ratio) is typically 1:2 or 1:3; in obstructive diseases, longer expiratory time prevents air trapping.

Parameters to Monitor

Monitoring prevents ventilator-induced injury. Plateau pressure, measured during an inspiratory pause, reflects alveolar pressure and should remain at or below 30 cmH2O. Peak pressure reflects airway resistance plus alveolar pressure; it is less specific but very high values (above 35-40 cmH2O) suggest problems. Driving pressure (plateau minus PEEP) correlates with mortality and should remain below 15 cmH2O. Auto-PEEP (intrinsic PEEP) from air trapping should be minimized, particularly in obstructive disease.

<image>Panel A: Four indications for intubation shown as icons: refractory hypoxemia with low SpO2 despite high-flow oxygen, hypercapnic failure with rising CO2 and confused patient, airway protection for aspiration risk with low GCS, and anticipated clinical decline with unstable trajectory. Panel B: Ventilator modes with waveforms: volume control with square flow waveform and variable pressure with set tidal volume labeled, pressure control with square pressure waveform and decelerating flow with set pressure labeled, and pressure support with patient-triggered breaths and patient-controlled timing. Panel C: Ventilator screen showing input settings of tidal volume in mL/kg IBW, respiratory rate, PEEP, and FiO2, alongside monitored output parameters of plateau pressure, peak pressure, driving pressure, and auto-PEEP with target ranges in green and danger zones in red. Panel D: Pressure-volume loop showing upper inflection point for overdistension, lower inflection point for atelectasis, and the safe operating range between them for optimal ventilator management.</image>

Ventilator Management and Liberation

The goals of ventilator management extend beyond gas exchange to include timely liberation from mechanical ventilation.

Daily Assessment Protocol

A structured daily approach improves outcomes. Sedation vacation (spontaneous awakening trial) involves pausing sedatives to assess neurological function, enabling earlier extubation and reducing delirium. A spontaneous breathing trial (SBT) tests readiness for extubation by having the patient breathe with minimal support. Early mobilization, even in ventilated patients, preserves muscle strength and function.

Readiness Criteria for SBT

Before attempting an SBT, patients should meet screening criteria: FiO2 of 40% or less, PEEP of 8 cmH2O or less, adequate respiratory drive (initiating breaths), hemodynamic stability without significant vasopressor requirements, and mental status adequate to follow commands.

Spontaneous Breathing Trial Methods

The T-piece trial involves disconnecting from the ventilator and breathing through the endotracheal tube with only supplemental oxygen—no ventilator support. Low pressure support involves minimal ventilator assistance (pressure support 5-8 cmH2O, PEEP 5 cmH2O). Both methods are valid; duration is typically 30-120 minutes.

SBT success is indicated by: respiratory rate less than 35 breaths per minute, SpO2 greater than 90%, no significant tachycardia or blood pressure changes, no excessive accessory muscle use, and no signs of distress. SBT failure criteria include tachypnea, desaturation, hemodynamic instability, diaphoresis, and agitation.

Extubation Considerations

Before extubation, assess factors predicting success or failure. Cough strength indicates ability to clear secretions; a weak cough predicts failure. Secretion quantity should be manageable. Cuff leak test assesses upper airway patency: with the cuff deflated, air should leak around the tube during positive pressure; absent leak suggests laryngeal edema and increased reintubation risk. Mental status must be adequate for airway protection.

Complications of Mechanical Ventilation

Prolonged mechanical ventilation carries risks that should be actively prevented. Ventilator-associated pneumonia (VAP) is reduced by head-of-bed elevation, oral care, minimizing ventilator duration, and subglottic secretion drainage. Barotrauma (pneumothorax, pneumomediastinum) is prevented by lung-protective ventilation. Ventilator-induced diaphragm dysfunction results from disuse atrophy; early weaning attempts and maintaining some spontaneous breathing preserve function. Delirium is minimized by reducing sedation, promoting sleep-wake cycles, and early mobilization.

<image>Panel A: Daily assessment flowchart branching to sedation vacation with morning pause clock icon and SBT readiness screening checklist including FiO2 40% or less, PEEP 8 or less, respiratory drive present, and stable hemodynamics. Panel B: Spontaneous breathing trial methods: T-piece with endotracheal tube connected to oxygen only, and low pressure support ventilation at 5/5 settings; success criteria of respiratory rate below 35, SpO2 above 90%, stable vitals, and no distress leading to extubation readiness assessment. Panel C: Extubation readiness assessment including cough strength test, secretion assessment, and cuff leak test, with green arrow to extubation and post-extubation support options of nasal cannula, HFNC, or NIV for at-risk patients; failure at any step loops back to identify reason, rest, and retry the next day. Panel D: Complications prevention panel showing VAP bundle with bed elevation, oral care, and minimized ventilator duration, plus other strategies including lung-protective ventilation, early mobility, and sedation minimization.</image>

Specific Clinical Scenarios

COPD Exacerbation

COPD exacerbation presents as acute-on-chronic hypercapnic respiratory failure. First-line ventilatory support is BiPAP (NIV), which reduces intubation rate and mortality. Initial settings typically include IPAP 10-15 cmH2O and EPAP 4-6 cmH2O, titrated upward as needed to reduce work of breathing and improve blood gases. The oxygen target is SpO2 88-92% to avoid suppressing hypoxic respiratory drive, which may be blunted in chronic hypercapnia. Key ventilator considerations if intubation becomes necessary include allowing adequate expiratory time to prevent air trapping, avoiding excessive PEEP that worsens hyperinflation, and tolerating moderate hypercapnia (permissive hypercapnia) rather than using harmful ventilator settings.

Cardiogenic Pulmonary Edema

Acute cardiogenic pulmonary edema presents with hypoxemic respiratory failure from alveolar flooding. CPAP or BiPAP is first-line ventilatory support, providing multiple benefits: increased intrathoracic pressure reduces venous return (preload), reduced transmural LV pressure decreases afterload, and alveolar recruitment improves oxygenation. NIV buys time for medical therapies (diuretics, vasodilators, inotropes if needed) to take effect. Most patients improve rapidly and can be weaned from NIV within hours.

Severe Asthma

Status asthmaticus requiring mechanical ventilation presents unique challenges. Dynamic hyperinflation and auto-PEEP are the primary concerns. Ventilator strategy emphasizes prolonged expiratory time: low respiratory rate (10-12 breaths/minute), small tidal volumes, and high inspiratory flow rates (to shorten inspiration and lengthen expiration). Permissive hypercapnia is accepted—tolerating elevated PaCO2 rather than using ventilator settings that worsen hyperinflation. Excessive PEEP should be avoided as it adds to auto-PEEP. Sedation and sometimes paralysis are needed to achieve patient-ventilator synchrony.

Neuromuscular Respiratory Failure

Patients with neuromuscular diseases (Guillain-Barré syndrome, myasthenic crisis, ALS) require close monitoring of respiratory muscle function. Serial measurements of forced vital capacity (FVC) and negative inspiratory force (NIF) guide management. Threshold for intubation is typically FVC less than 15-20 mL/kg or declining rapidly, NIF less than -30 cmH2O, or clinical signs of respiratory fatigue. NIV may serve as a temporizing measure but is not definitive. Recovery may be prolonged, requiring extended ventilator support. Early tracheostomy should be considered if prolonged ventilation is anticipated.

<image>Panel A: COPD exacerbation showing patient with barrel chest and pursed-lip breathing on BiPAP mask with settings IPAP 12 and EPAP 5, SpO2 target 88-92%, and key management pearls of avoiding over-oxygenation and air trapping. Panel B: Cardiogenic pulmonary edema showing patient sitting upright with pink frothy sputum icon on CPAP mask, mechanism arrows demonstrating reduced preload and afterload, with rapid improvement expected from NIV. Panel C: Severe asthma showing patient with accessory muscle use on ventilator with low rate of 10 breaths per minute, prolonged expiration at I:E ratio 1:4, auto-PEEP waveform, and key issue of permissive hypercapnia acceptance. Panel D: Neuromuscular respiratory failure showing patient with weak cough, bedside spirometer measuring FVC, NIF gauge with threshold values for intubation of FVC below 20 mL/kg and NIF below negative 30, and clock indicating the need for serial measurements.</image>

Summary

Type I (hypoxemic) respiratory failure is defined by PaO2 less than 60 mmHg and results from V/Q mismatch, shunt, diffusion impairment, or hypoventilation. Shunt is distinguished by poor response to supplemental oxygen.

Type II (hypercapnic) respiratory failure is defined by PaCO2 greater than 50 mmHg and results from impaired ventilation at any level from CNS to lung, or from increased dead space.

ARDS is characterized by bilateral infiltrates, PaO2/FiO2 ratio of 300 or less with PEEP of at least 5, onset within one week, and non-cardiogenic origin. Lung-protective ventilation (tidal volume 4-6 mL/kg IBW, plateau pressure at or below 30 cmH2O, driving pressure less than 15 cmH2O) is essential.

Prone positioning improves mortality in moderate-severe ARDS and should be used for 16 or more hours daily.

NIV is first-line for COPD exacerbation and cardiogenic pulmonary edema, reducing intubation rates and mortality.

High-flow nasal cannula provides high-flow oxygen with modest PEEP effect and improved comfort compared to masks.

Liberation from mechanical ventilation requires daily sedation vacations and spontaneous breathing trials; early extubation reduces complications.

Key Terms

This content is subject to the MIT License. © 2024–2026 Hibbert School of Medicine.

Read this lecture as Markdown